Latest Breaking News On - Immunobiochem corporation - Page 1 : comparemela.com

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesBob chenHanall biopharmaMatt foehrImmunobiochem corporationTrademark officeAmerican society of clinical oncologyMerck kgaaMerck kgaNational medical products administration of chinaOmniab incAmerican association for cancer research annual meetingUniversity of georgiaChief executive officerRecent businessAll biopharma

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

02.11.2023 - ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023. .

United statesHeather adkins huetEli lillyCompany annual report on formAmerican society of hematologyExchange commission onDrug administrationImmunobiochem corporationNovartis institutes for biomedical research incEuropean society of gynaecological oncologyNational medical products administrationExchange commissionImmunogen incTakeda pharmaceutical company limitedCompany quarterly reports on formEuropean medicines agency

ImmunoBiochem Announces Multi-Target License and Option Agreement with ImmunoGen to Develop Next-Generation Antibody-Drug Conjugates

TORONTO - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics, announced today a.

Anton neschadimEric westinTranslational sciencesImmunobiochem corporationClinical developmentImmunogen incBiochem corporationVice presidentJohnson innovationNews publishing

ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates

ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Courtney okonekEric westinAnton neschadimRobert stanislaroAnabel chanImmunogen incExchange commission onCompany annual report on formClinical developmentImmunobiochem corporationPayload technologyCompany quarterly reports on formUniversity of torontoPartnership to incorporate additionalTranslational sciencesExchange commission

ImmunoBiochem Announces Multi-Target License and Option Agreement with ImmunoGen to Develop Next-Generation Antibody-Drug Conjugates

/PRNewswire/ - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel.

Eric westinAnton neschadimImmunobiochem corporationUniversity of torontoClinical developmentImmunogen incTranslational sciencesBiochem corporationVice presidentJohnson innovation